Shopping Cart
- Remove All
- Your shopping cart is currently empty
Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $115 | In Stock | |
5 mg | $228 | In Stock | |
10 mg | $380 | In Stock | |
25 mg | $685 | In Stock | |
50 mg | $998 | In Stock | |
100 mg | $1,500 | In Stock |
Description | Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs. |
Targets&IC50 | Atg4B:3.1 μM (Ki), Atg4B:11 μM, PLA2:3.5 μM |
In vitro | In a dose-dependent manner, Atg4B-IN-2 (compound 21f) (1-10 μM; 2 hours) restores p62 expression in cells treated with amino acid-free (AF) conditions [1]. At concentrations of 1 and 5 μM (2 hours), Atg4B-IN-2 moderately decreases autophagic vesicles at 1 μM and almost completely inhibits autophagy at 5 μM [1]. At a concentration of 5 μM (2 hours), Atg4B-IN-2 inhibits Abi-induced autophagy, significantly enhances apoptotic cell death, and increases sensitivity to Abi [1]. |
Molecular Weight | 330.46 |
Formula | C21H30O3 |
Cas No. | 2765008-88-4 |
Smiles | C(/C=C/C(O)=O)(=O)C1=CC=C(CCCCCCCCCCC)C=C1 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (242.09 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.